Cells in the body have to move around in order to do their jobs. During development, for instance, cells are distributed to ...

The research focuses on cells’ “feet,” which are small bundles of molecules that help cells move. Scientists are exploring ...

A bill that would ban the use of mRNA vaccines, including for Covid-19, is on its way to the House floor after passing out of committee in a party-line vote Wednesday. Sponsored by Rep. Greg Kmetz, ...

Moderna (MRNA) came out with a quarterly loss of $2.50 per share versus the Zacks Consensus Estimate of a loss of $2.69. This compares to earnings of $0.55 per share a year ago. These figures are ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

The company is now expecting 2025 revenue to range from $1.5 billion to $2.5 billion, with a midpoint of $2.0 billion, while FactSet is expecting $2.4 billion. Most of that will come in the second ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

Moderna Inc.'s stock fell 2.9% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered soft guidance for 2025, offsetting a revenue beat.

Moderna Inc. (MRNA) on Friday reported a loss of $1.12 billion in its fourth quarter. On a per-share basis, the ...

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down ...